Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Keros Therapeutics (KROS) PT Lowered to $23 at Jefferies
December 13, 2024 5:21 AM ESTJefferies analyst Kelly Shi lowered the price target on Keros Therapeutics (NASDAQ: KROS) to $23.00 (from $113.00) while maintaining a Buy rating.
The analyst comments "Unexpectedly, KROS discontinued two higher doses of cibotercept in Ph2 PAH due to pericardiac AEs, which were not seen in... More
TD Cowen Downgrades Keros Therapeutics (KROS) to Hold
December 12, 2024 9:45 AM ESTTD Cowen analyst Tyler Van Buren downgraded Keros Therapeutics (NASDAQ: KROS) from Buy to Hold.
The analyst comments "Following the unexpected occurrence of pericardial effusion, Keros has halted dosing in the 3.0 and 4.5mg/kg arms and will continue at 1.5mg/kg.... More
